US Markets
Home›US Markets›Equities›Lifecore Biomedical outdraws benchmarks as fund cites…
Lifecore Biomedical outdraws benchmarks as fund cites new contract wins
In the fund letter, Lifecore shares closed at $4.61 on July 14, and the stock has fallen 39.9% over the past 52 weeks.
Laughing Water Capital said its Q2 2026 portfolio produced standout results, with Class A investment returning about 39.8% net of fees and expenses for the quarter and about 33.6% year-to-date, compared with roughly 15.0% for the SP500TR and 21.5% for the R2000, according to the Yahoo Finance account of the fund’s second-quarter investor letter.
Within that update, the firm highlighted Lifecore Biomedical, Inc. (NASDAQ: LFCR), describing the company as an integrated contract development and manufacturing organization focused on aseptic fill and finish for sterile injectable products and medical device offerings.
Yahoo Finance also notes that Lifecore closed at $4.61 per share on July 14, 2026, valuing the company at about $172.9 million, and that the stock showed a one-month move of -16.5% and a 52-week decline of about 40.0%.
In the investor update, the fund argued that Lifecore’s “under-utilized” fill-finish business continues to win new customers at a strong pace, and it linked that pipeline to potential operating leverage once new business converts into revenue, while also pointing to a post-quarter 8-K about Series A Preferred Stock redemptions and the company evaluating strategic alternatives.
Latest closeNasdaq Comp. 26,269.23 ▲0.6%